// App-Quantinova.ai

2738 : Phase II Multicenter Study of the Safety and Efficacy of Single-Agent Lenalidomide in Subjects with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Follow-up Analysis of the NHL-003 Study.

Researchers

Presenter

  • Julie M Vose

Principal Investigators

  • Myron S. Czuczman

  • Craig Reeder

  • Corinne Haioun

  • Jonathan Polikoff

  • Herve Tilly

  • Dennis Pietronigro

  • Annette Ervin-Haynes

  • Ju Li

  • Thomas E. Witzig

Medical Centers

  • Istituto di Ematologia, Bologna, Italy

  • Hopital Henri Mondor, Unite Hemopathies Lymphoide, Creteil, France

  • CRLCC Henri Becquerel, Rouen, France

  • Southern California Liver Center, San Diego, CA

Locations

  • France

  • United States

  • Italy

Companies

  • Celgene Corporation

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Cutaneous squamous cell carcinoma

  • Non-Hodgkin's Lymphoma

  • Mantle cell lymphoma

  • Deep vein thrombosis

  • Hodgkin's Lymphoma

  • Thrombocytopenia

  • Neutropenia

  • Non‐Hodgkin Lymphoma

  • Venous thrombosis

  • Solid malignancies

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • Lenalidomide

Outcome

  • N/A

Study Design

  • open label

  • double blind/blinded

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved